A new analysis in pharmacovigilance reports that liver injury after CAR T-cell therapy often tracks with cytokine release syndrome timing, with an early-onset signal dominating. The dataset also suggests a persistent CRS-independent component tied to idecabtagene vicleucel that warrants prospective confirmation. For perioperative and survivorship care, a preclinical-to-clinical shift is also visible: a study suggests that reframing opioid dosing around pain rather than fixed schedules could help separate therapeutic use from addiction risk in long-term cancer survivors. While framed as a commentary, it reflects a growing emphasis on risk-calibrated treatment strategies. In imaging-guided medicine, a prospective study indicates that 68Ga-Pentixafor PET/CT can match adrenal venous sampling for lateralizing aldosterone-producing adenomas even when patients remain on mineralocorticoid receptor antagonists. Reducing reliance on invasive sampling could also narrow procedure-related safety risks.